Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma

Overview

Journal Mol Cancer Res

Specialty Cell Biology

Date 2023 Feb 15

PMID 36790391

Authors

Jessica Limberg

Caitlin E Egan

Katherine D Gray

Mandeep Singh

Zachary Loewenstein

Yanping Yang

Maria Cristina Riascos

Hala Al Asadi

Parima Safe

Steve El Eshaky

Heng Liang

Timothy M Ullmann

Weibin Wang

Wei Li

Tuo Zhang

Jenny Xiang

Dessislava Stefanova

Moonsoo M Jin

Rasa Zarnegar

Thomas J Fahey

Irene M Min

Affiliations

Soon will be listed here.

Abstract

Implications: Dual inhibition of BRAF and JAK/STAT signaling pathway is a potential therapeutic treatment for anticancer activity and to overcome drug resistance to BRAFi in thyroid cancer.

Citing Articles

Ruxolitinib induces apoptosis and pyroptosis of anaplastic thyroid cancer via the transcriptional inhibition of DRP1-mediated mitochondrial fission.

Guo Y, Zhu L, Duan Y, Hu Y, Li L, Fan W Cell Death Dis. 2024; 15(2):125.

PMID: 38336839 PMC: 10858168. DOI: 10.1038/s41419-024-06511-1.

The Role of Inflammation-Associated Factors in Head and Neck Squamous Cell Carcinoma.

Li K, Zeng X, Liu P, Zeng X, Lv J, Qiu S J Inflamm Res. 2023; 16:4301-4315.

PMID: 37791117 PMC: 10544098. DOI: 10.2147/JIR.S428358.

Dysregulated Signalling Pathways Driving Anticancer Drug Resistance.

Bou Antoun N, Chioni A Int J Mol Sci. 2023; 24(15).

PMID: 37569598 PMC: 10418675. DOI: 10.3390/ijms241512222.

References

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

Parker B, Rautela J, Hertzog P . Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016; 16(3):131-44. DOI: 10.1038/nrc.2016.14. View

Min I, Shevlin E, Vedvyas Y, Zaman M, Wyrwas B, Scognamiglio T . CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors. Clin Cancer Res. 2017; 23(24):7569-7583. PMC: 5732861. DOI: 10.1158/1078-0432.CCR-17-2008. View

Smallridge R, Ain K, Asa S, Bible K, Brierley J, Burman K . American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012; 22(11):1104-39. DOI: 10.1089/thy.2012.0302. View

Lu H, Liu S, Zhang G, Wu B, Zhu Y, Frederick D . PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2017; 550(7674):133-136. PMC: 5891348. DOI: 10.1038/nature24040. View

Cabanillas M, Dadu R, Iyer P, Wanland K, Busaidy N, Ying A . Acquired Secondary RAS Mutation in BRAF-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid. 2020; 30(9):1288-1296. PMC: 7869871. DOI: 10.1089/thy.2019.0514. View

Montero-Conde C, Ruiz-Llorente S, Dominguez J, Knauf J, Viale A, Sherman E . Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013; 3(5):520-33. PMC: 3651738. DOI: 10.1158/2159-8290.CD-12-0531. View

Schweppe R, Klopper J, Korch C, Pugazhenthi U, Benezra M, Knauf J . Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008; 93(11):4331-41. PMC: 2582569. DOI: 10.1210/jc.2008-1102. View

Dobin A, Davis C, Schlesinger F, Drenkow J, Zaleski C, Jha S . STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2012; 29(1):15-21. PMC: 3530905. DOI: 10.1093/bioinformatics/bts635. View

10.

Subbiah V, Kreitman R, Wainberg Z, Cho J, Schellens J, Soria J . Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2017; 36(1):7-13. PMC: 5791845. DOI: 10.1200/JCO.2017.73.6785. View

11.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

12.

Kim H, Frederick D, Levesque M, Cooper Z, Feng Y, Krepler C . Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Rep. 2015; 11(9):1458-73. PMC: 4681438. DOI: 10.1016/j.celrep.2015.04.049. View

13.

Gunda V, Bucur O, Varnau J, Vanden Borre P, Bernasconi M, Khosravi-Far R . Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. Cell Death Dis. 2014; 5:e1104. PMC: 3973207. DOI: 10.1038/cddis.2014.78. View

14.

Dralle H, Machens A, Basa J, Fatourechi V, Franceschi S, Hay I . Follicular cell-derived thyroid cancer. Nat Rev Dis Primers. 2016; 1:15077. DOI: 10.1038/nrdp.2015.77. View

15.

Pozdeyev N, Gay L, Sokol E, Hartmaier R, Deaver K, Davis S . Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin Cancer Res. 2018; 24(13):3059-3068. PMC: 6030480. DOI: 10.1158/1078-0432.CCR-18-0373. View

16.

Propper D, Chao D, Braybrooke J, Bahl P, Thavasu P, Balkwill F . Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clin Cancer Res. 2003; 9(1):84-92. View

17.

Trapnell C, Williams B, Pertea G, Mortazavi A, Kwan G, van Baren M . Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010; 28(5):511-5. PMC: 3146043. DOI: 10.1038/nbt.1621. View

18.

Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf J, Shah R . Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016; 126(3):1052-66. PMC: 4767360. DOI: 10.1172/JCI85271. View

19.

Brose M, Cabanillas M, Cohen E, Wirth L, Riehl T, Yue H . Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016; 17(9):1272-82. PMC: 5532535. DOI: 10.1016/S1470-2045(16)30166-8. View

20.

Long G, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J . Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015; 386(9992):444-51. DOI: 10.1016/S0140-6736(15)60898-4. View